Insider Selling: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Sells $16,922.50 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 250 shares of ANI Pharmaceuticals stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $67.69, for a total value of $16,922.50. Following the completion of the transaction, the vice president now owns 59,481 shares in the company, valued at $4,026,268.89. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Meredith Cook also recently made the following trade(s):

• On Friday, April 12th, Meredith Cook sold 250 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $67.79, for a total value of $16,947.50.
• On Tuesday, February 13th, Meredith Cook sold 250 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $56.04, for a total transaction of $14,010.00.

ANI Pharmaceuticals Price Performance

Shares of ANIP stock traded down $0.21 during mid-day trading on Thursday, reaching $64.61. The stock had a trading volume of 14,847 shares, compared to its average volume of 136,288. ANI Pharmaceuticals, Inc. has a 12-month low of $43.32 and a 12-month high of $70.81. The company has a current ratio of 3.95, a quick ratio of 3.12 and a debt-to-equity ratio of 0.63. The business has a 50-day simple moving average of $66.96 and a 200 day simple moving average of $59.63. The company has a market cap of $1.36 billion, a P/E ratio of 40.51 and a beta of 0.80.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The company had revenue of $131.65 million during the quarter, compared to analysts’ expectations of $123.02 million. ANI Pharmaceuticals had a net margin of 6.87% and a return on equity of 17.15%. On average, sell-side analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.55 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages recently commented on ANIP. HC Wainwright raised their price objective on shares of ANI Pharmaceuticals from $83.00 to $87.00 and gave the company a “buy” rating in a research report on Monday. Capital One Financial started coverage on ANI Pharmaceuticals in a report on Friday, March 15th. They issued an “overweight” rating and a $80.00 price target for the company. Truist Financial increased their price objective on ANI Pharmaceuticals from $72.00 to $80.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Finally, Guggenheim restated a “buy” rating and set a $77.00 target price on shares of ANI Pharmaceuticals in a research report on Tuesday, April 23rd. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $81.00.

Institutional Investors Weigh In On ANI Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. raised its holdings in shares of ANI Pharmaceuticals by 93.6% in the third quarter. China Universal Asset Management Co. Ltd. now owns 513 shares of the specialty pharmaceutical company’s stock worth $30,000 after acquiring an additional 248 shares during the last quarter. Pacer Advisors Inc. purchased a new position in ANI Pharmaceuticals in the 4th quarter valued at about $41,000. AJOVista LLC purchased a new position in ANI Pharmaceuticals in the 4th quarter valued at about $58,000. SG Americas Securities LLC acquired a new stake in shares of ANI Pharmaceuticals during the 1st quarter worth about $106,000. Finally, ADAR1 Capital Management LLC purchased a new stake in shares of ANI Pharmaceuticals during the fourth quarter worth about $132,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.